STOCK TITAN

MapLight Therapeutics (MPLT) Stock News

MPLT NASDAQ

MapLight Therapeutics, Inc. (Nasdaq: MPLT) is a clinical-stage biopharmaceutical company focused on debilitating central nervous system disorders, and its news flow reflects the progress of a multi-program CNS pipeline. Company announcements describe clinical trial milestones, regulatory designations, financial updates, and research collaborations tied to its circuit-focused drug discovery approach.

Recent news highlights include updates on Phase 2 studies such as ZEPHYR for schizophrenia and IRIS for autism spectrum disorder, along with the VISTA trial for hallucinations and delusions associated with Alzheimer’s disease psychosis. MapLight has reported accelerated enrollment in certain trials and provided guidance on expected timing for topline results, which are key events for investors and observers tracking the development of its product candidates.

The company has also disclosed that the U.S. Food and Drug Administration granted Fast Track designation to ML-007C-MA for Alzheimer’s disease psychosis, and that a Phase 1 study showed a generally favorable safety and tolerability profile in healthy elderly participants. In addition, MapLight has announced a strategic collaboration with SandboxAQ to apply AI-driven molecular simulation to novel G protein-coupled receptor targets for CNS disorders.

News items further cover MapLight’s initial public offering on the Nasdaq Global Select Market under the symbol MPLT, a concurrent private placement, and subsequent financial updates. Visitors to this page can review these press releases and other company communications to follow clinical progress, regulatory interactions, capital markets activity, and partnership developments related to MapLight’s CNS-focused pipeline.

Rhea-AI Summary

MapLight Therapeutics (Nasdaq: MPLT) reported a third-quarter net loss of $51.6 million while advancing its planned schizophrenia trial, ZEPHYR-2. The loss compared with $29.4 million a year earlier. Research and development expenses rose to $44.2 million from $27.1 million; general and administrative expenses increased to $11.1 million from $4.4 million.

Cash, cash equivalents and investments totaled $463.4 million at September 30, 2026, following an August $150 million private placement. MapLight expects funding to support ML-007C-MA through 2028. ZEPHYR-2 start-up activities have begun, with results expected in 2028; an FDA meeting is planned to discuss the registration path. Enrollment continues in the Phase 2 VISTA study in Alzheimer’s disease psychosis, with results expected in the second half of 2027. MapLight is pausing significant further investment in preclinical and discovery programs beyond near-term milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
-
Rhea-AI Summary

MapLight Therapeutics (MPLT) will participate in the Jefferies Global Healthcare Conference in London on November 18, 2026. Management will present and host one-on-one meetings. Where available, live webcasts and archived recordings will be posted on the company’s investor website under Events & Presentations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.20%
Tags
conferences
-
Rhea-AI Summary

MapLight Therapeutics (MPLT) celebrated co-founder Karl Deisseroth’s receipt of the 2026 Nobel Prize in Physiology or Medicine for discoveries concerning optogenetics.

Deisseroth, a Scientific Advisory Board member, shares the award with Peter Hegemann and Georg Nagel for discoveries concerning light-gated ion channels and optogenetics, tools for studying nerve-cell activity. His work inspired MapLight’s founding in 2018.

The Phase 2 ZEPHYR study of ML-007C-MA met its primary endpoint, showing statistically significant and clinically meaningful improvement in schizophrenia symptoms. MapLight intends to meet with the FDA and subsequently initiate Phase 3. It also intends to meet with the FDA to discuss a planned Phase 3 program in irritability associated with autism following Phase 2 IRIS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.47%
Tags
none
Rhea-AI Summary

MapLight Therapeutics (MPLT) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14. The company’s management will present and host 1x1 investor meetings during the event.

Where available, live and archived webcasts will be posted on the Investor section of MapLight’s website under the “Events & Presentations” page at https://ir.maplightrx.com/news-events/events-presentations. MapLight is a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
conferences
-
Rhea-AI Summary

MapLight Therapeutics (Nasdaq: MPLT) reported second quarter 2026 results and a business update, highlighting positive topline data from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia. The study met its primary endpoint, showing a statistically significant and clinically meaningful PANSS total score reduction at Week 5 versus placebo at the 210/3 mg twice-daily dose, plus improvements on prespecified cognitive and key secondary endpoints, with a generally well-tolerated safety profile. MapLight plans an End-of-Phase 2 FDA meeting and a Phase 3 ZEPHYR-2 trial, with topline results expected in 2028.

ML-007C-MA is also in the Phase 2 VISTA trial for Alzheimer’s disease psychosis, which has FDA Fast Track designation and topline data expected in the second half of 2027. The company reported Phase 2 IRIS results for ML-004 in autism spectrum disorder; the trial did not meet its primary endpoint, although a prespecified adolescent subgroup showed clinically meaningful improvements in irritability. MapLight ended the quarter with $351.3 million in cash, cash equivalents and investments and, together with a recent $150 million private placement, expects to fund ML-007C-MA through 2028. Quarterly R&D expenses were $53.4 million, G&A expenses were $10.1 million, and net loss was $60.2 million, all higher than the prior-year period, as the company focuses resources on advancing ML-007C-MA and pauses preclinical and discovery-stage programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
-
Rhea-AI Summary

MapLight Therapeutics (Nasdaq: MPLT) entered a securities purchase agreement for a private placement (PIPE) expected to raise approximately $150 million in gross proceeds. The company is selling 9,197,887 common shares at $11.38 per share and pre-funded warrants for up to 3,983,168 shares at $11.3799 each, with a $0.0001 exercise price.

The PIPE, led by new and existing institutional investors, is expected to close on August 14, 2026, subject to customary conditions. According to MapLight Therapeutics, proceeds will primarily fund advancement of ML-007C-MA, including the VISTA Phase 2 Alzheimer’s psychosis study, the ZEPHYR-2 registrational Phase 3 schizophrenia program, related safety study, and general corporate purposes. With $351.3 million in cash, equivalents and investments as of June 30, 2026, the company expects this financing to fund ML-007C-MA development through 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
private placement
Rhea-AI Summary

MapLight Therapeutics (Nasdaq: MPLT) reported positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in adults with acute exacerbation of schizophrenia. The 210/3 mg twice-daily dose met the primary endpoint, delivering a statistically significant reduction in PANSS total score versus placebo at Week 5 (effect size 0.37; LS mean difference -4.5; p=0.015) in the mITT population and an effect size of 0.50 (LS mean difference -6.0; p=0.002) in completers.

The BID dose also achieved significance on key secondary measures including CGI-S (effect size 0.48; p=0.002), PANSS positive Marder factor (effect size 0.39; p=0.012), and showed a notable cognitive benefit in patients with baseline cognitive impairment (effect size 0.51; 0.44-point improvement; p=0.041). ML-007C-MA was generally well tolerated, with no serious or drug-related severe adverse events and low GI-related discontinuations (2.0% at BID). MapLight plans an End-of-Phase 2 FDA meeting and additional registrational trials, including a Phase 3 study in schizophrenia and ongoing VISTA trial in Alzheimer’s disease psychosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-72.91%
Tags
-
Rhea-AI Summary

MapLight Therapeutics (Nasdaq: MPLT) appointed Martin Babler and Troy Cox to its Board of Directors following their June 23, 2026 annual meeting. They succeed Robert Malenka and Jim Trenkle. Babler joins the Audit Committee, while Cox becomes Chair of the Nominating and Corporate Governance Committee.

Both new directors have prior CEO and senior leadership experience at multiple biotechnology and pharmaceutical companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
management
-
Rhea-AI Summary

MapLight (Nasdaq:MPLT) reported topline Phase 2 IRIS results for ML-004 in autism spectrum disorder. The trial (N=161) did not meet its primary endpoint on ABI Social Communication. In a prespecified adolescent subgroup with baseline ABC-I ≥16 (N=20), ML-004 showed substantial irritability improvement vs placebo on ABC-I (LS mean −9.58; ES 1.33; nominal p=0.013) and clinician-rated CGI-I irritability (ES 1.08; nominal p=0.036).

ML-004 was generally well-tolerated, with no severe or serious adverse events, no extrapyramidal events, and lower mean weight gain than placebo. MapLight plans an FDA End-of-Phase 2 meeting and reports being well capitalized ahead of Phase 2 ZEPHYR (ML-007C-MA) schizophrenia data expected by mid-August 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
Rhea-AI Summary

MapLight Therapeutics (Nasdaq:MPLT) reported first quarter 2026 results and key clinical milestones.

Enrollment completed in the Phase 2 ZEPHYR schizophrenia trial (307 participants) and last patient visit completed in the Phase 2 IRIS autism trial (161 participants), with topline data from both expected by mid-August 2026.

Phase 2 VISTA in Alzheimer’s disease psychosis is enrolling, with topline data expected in the second half of 2027. Cash, cash equivalents and investments totaled $395.2 million, expected to fund operations through 2027. Q1 2026 R&D was $53.7 million, G&A $10.8 million, and net loss $60.7 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags

FAQ

What is the current stock price of MapLight Therapeutics (MPLT)?

MapLight Therapeutics (MPLT) last closed at $6.57.

What is the market cap of MapLight Therapeutics (MPLT)?

The market cap of MapLight Therapeutics (MPLT) is approximately $369.3M.